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The nicotinamide adenine dinucleotide phosphate (NADPH)
oxidases (NOXs) comprise a complex multicomponent family
of transmembrane proteins that use NADPH as the electron
donor to reduce molecular oxygen to superoxide anion and
hydrogen peroxide. The prototype NADPH oxidase is NOX2
(formerly known as gp91phox), which was ﬁrst described in
leukocytes as amediator of host defense that acts by generating
large quantities of superoxide and derivative downstream
reactive oxygen species (ROS) that are involved in bacterial
killing (1). Subsequent studies characterized 7 members of
the NOX family (NOX1 to 5 and dual oxidase 1 and 2)
with diverse distributions among speciﬁc tissues and organsSee page 2734(1,2). Four NOX isoformsdNOX1, NOX2, NOX4, and
NOX5dare expressed in the heart, and they have distinct
cellular distributions. NOX2 and NOX4 are expressed in
coronary endothelial cells, cardiomyocytes, and ﬁbroblasts,
whereas NOX1 and NOX4 are expressed in coronary smooth
muscle cells. In endothelial cells, NOX4 appears to be
constitutively active, whereas NOX2 activity is regulated and
can be activated by G-protein–coupled receptor agonists
such as angiotensin II and endothelin, growth factors such
as vascular endothelial growth factor, and the mechanical
effects of shear stress from the ﬂowing blood. In the healthy
organism,NOX2 and other NOX isoforms normally generate
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this paper to disclose.that contribute to the normal physiological responses to a
variety of biological stimuli. However, pathological activation
of NOX2 (e.g., by cytokines such as tumor necrosis factor-
alpha) can result in generation of much higher concentra-
tions ofROS that are characteristic of and appear to contribute
to pathological states including endothelial dysfunction,
myocardial hypertrophy and ﬁbrosis, and heart failure (2).
There is substantial evidence that NOX2 also plays an
important deleterious role in the development and progression
of clinical conditions such as atherosclerosis, coronary artery
disease, stroke, and renal and pulmonary ﬁbrosis (2).
Chronic activation of the renin-angiotensin system is
known to result in myocardial hypertrophy, ﬁbrosis, and
inﬂammation. The downstream events for these pathological
effects of angiotensin II involve NOX2-mediated vascular
smooth muscle hypertrophy and perivascular ﬁbrosis via the
production of ROS (3,4). NOX2 is also important in
angiotensin II–induced expression of adhesion molecules
that mediate leukocyte attachment to the endothelium and
subsequent perivascular inﬁltration. Previous studies dem-
onstrated that NOX2 knockout attenuated angiotensin
II– and myocardial infarct–induced myocardial ﬁbrosis and
cardiomyocyte hypertrophy in mice (5,6). Although NOX2
knockout had no detectable effect on the left ventricular
(LV) hypertrophy produced by chronic systolic overload
secondary to transverse aortic banding in mice (7,8), NOX2
knockout did signiﬁcantly attenuate aortic banding–induced
myocardial ﬁbrosis (8). However, the cellular speciﬁc effects
of NOX2 on angiotensin II–induced ventricular ﬁbrosis and
cardiac dysfunction have been uncertain.
In this issue of the Journal,Murdoch et al. (9) report studies
examining the contributions of ROS derived from NOX2
within the vascular endothelium andNOX2within leukocytes
to the adverse cardiac remodeling caused by renin-angiotensin
activation. Because NOX2 is expressed in multiple cell types
in the heart including endothelial cells, cardiomyocytes, and
ﬁbroblasts, as well as in inﬂammatory cells that can invade the
heart during pathological conditions, the investigators ﬁrst
used a geneticallymodiﬁedmouse strainwithw2-foldNOX2
overexpression conﬁned speciﬁcally to the vascular endothe-
lium (3). During unstressed conditions, these endothelial-
speciﬁc NOX2 transgenic mice are normotensive, with
normal cardiac structure and function (9). In response to a 2-
week infusion of angiotensin II, wild-type and NOX2
transgenic mice developed similar degrees of systolic hyper-
tension and moderate but comparable LV hypertrophy (9).
However, the NOX2 transgenic mice developed a 2-fold
greater degree of myocardial ﬁbrosis than did the wild-type
animals, and this was associated with smaller diastolic LV
volumes (9). The greater extent of leukocyte inﬁltration and
myocardial ﬁbrosis in the NOX2 transgenic mice was abol-
ished by treatment with the antioxidant N-acetylcysteine, a
ﬁnding implying that the more severe pathologic features in
the NOX2 transgenic mice were ROS dependent. The time
constant of LV relaxation (tau) was not different between
transgenic and wild-type mice exposed to angiotensin II
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2743infusion, but the end-diastolic pressure-volume relationship
was shifted to the left in the transgenic mice (9). These
ﬁndings suggest that the material property of the ventricle,
rather than abnormal cross-bridge detachment, was respon-
sible for the stiffer hearts in the transgenic animals. The
increased chamber stiffness in the presence of increasedﬁbrosis
is not surprising, but it provides an interesting animal model
of diastolic dysfunction with preserved systolic function. LV
end-diastolic pressures were not signiﬁcantly elevated in the
transgenic mice during the 2-week angiotensin II infusion
period, but it would be interesting to know whether evidence
of congestion would occur with longer observation periods.
Angiotensin II causes increased expression of endothelial
adhesion molecules such as intercellular adhesion molecule-1
and vascular adhesion molecule (VCAM)-1, which promote
attachment of leukocytes to the endothelium and subsequent
inﬁltration into the perivascular zone. Because NOX2 is
highly abundant in leukocytes, it may be expected that
leukocyte NOX2 would contribute to the angiotensin II–
induced myocardial ﬁbrosis. To examine the role of NOX2
within leukocytes, the investigators used chimeric mice with
differing NOX2 genotypes in resident tissue cells and in bone
marrow–derived cells (9). By transplanting bone marrow from
wild-type mice into global NOX2 knockout mice with
radiation-induced bone marrow ablation, the investigators
generated mice with NOX2 competent circulating cells but
lacking endothelial NOX2. These NOX2 knockout mice
with bone marrow from wild-type mice had reduced cardiac
ﬁbrosis in response to angiotensin II infusion, similar to
intact NOX2 knockout mice. Thus, the presence of NOX2-
competent bone marrow–derived cells did not increase the
degree of myocardial ﬁbrosis when NOX2 was absent from
the endothelium. In contrast, wild-type mice with intact
endothelial NOX2 that had their bone marrow reconstituted
from global NOX2 knockout mice developed myocardial
ﬁbrosis in response to angiotensin II infusion that was similar
to ﬁndings in wild-type mice. Thus, the lack of NOX2 in
marrow-derived cells did not reduce the degree of myocardial
ﬁbrosis that occurred in response to angiotensin II infusion.
Furthermore, transgenic mice with endothelial-speciﬁc over-
expression of NOX2 that had bone marrow reconstituted
from wild-type mice developed more cardiac ﬁbrosis than did
wild-type mice with normal endothelial NOX2 expression.
As expected, wild-type mice with bone marrow reconstituted
from NOX2 transgenic mice developed myocardial ﬁbrosis
similar to that seen in wild-type mice in response to angio-
tensin II because the NOX2 overexpression was conﬁned
to the endothelium. Angiotensin II caused more VCAM-1
expression in coronary microvascular endothelial cells isolated
from NOX2 transgenic mice than in coronary microvascular
endothelial cells isolated from wild-type mice. VCAM-
1–positive blood vessels were also signiﬁcantly increased in
NOX2 transgenic mice as compared with wild-type mice after
angiotensin II infusion (9).
Taken together, the investigators provided evidence that
NOX2 in the endothelium plays a critical role in thedevelopment of myocardial ﬁbrosis and LV diastolic
dysfunction that develops in response to angiotensin II.
ROS generated by endothelial NOX2 is essential for the
increased endothelial expression of adhesion molecules that
promote inﬁltration of inﬂammatory cells into the myocar-
dium in response to angiotensin II. Although not reported,
it would be important to know whether genetic manipula-
tion of NOX2 in the endothelium caused similar alterations
of macrophage inﬁltration into the myocardium of all
animals studied. Thus, if the circulating bone marrow–
derived cells failed to adhere to and penetrate the endo-
thelium in the studies in which NOX2 knockout animals
were transplanted with wild-type bone marrow, then the
failure of inﬂammatory cells to invade the myocardium,
even though these cells contained NOX2 and were able to
generate ROS, could explain the failure of the NOX2-
competent cells to produce the same degree of ﬁbrosis
seen in the wild-type animals. In other words, did sup-
pression of endothelial adhesion molecule expression in the
NOX2 knockout animals prevent myocardial invasion by the
NOX2-competent inﬂammatory cells? This is important
because it would distinguish whether a lack of cell inﬁltra-
tion into the myocardium accounted for the decreased
ﬁbrosis and diastolic dysfunction in the NOX2 knockout
animals or whether some other function of endothelium-
derived NOX2-generated ROS was responsible for the
myocardial ﬁbrosis and diastolic dysfunction.
To explore mechanisms by which NOX2 may promote
myocardial ﬁbrosis on stimulation with angiotensin II further,
the authors examined hearts for evidence of endothelial-
mesenchymal transition. Endothelial-mesenchymal transi-
tion has been well described during cardiac development, and
more recent reports have demonstrated that this phenomenon
contributes to the myocardial ﬁbrosis that develops in
response to chronic LV pressure overload or diabetes in
mice (10–12). In these pathological states, endothelial cells
lose their speciﬁc markers and develop a mesenchymal or
myoﬁbroblast phenotype with invasive potential and the
ability to produce mesenchymal cell products including type 1
collagen (10,12). The authors found that angiotensin II–
treated transgenic hearts exhibited increased co-localization of
endothelial-speciﬁc and mesenchymal markers compared
with wild-type hearts. They also found that angiotensin II
caused an increase in ﬁbroblast-speciﬁc markers and a
decrease in endothelial-speciﬁc markers in cultured aortic
endothelial cells and that this transition was augmented by
NOX2-overexpressing cells. The degree to which this phe-
nomenon contributes tomyocardial ﬁbrosis in the angiotensin
II–treated heart, and the speciﬁc downstream pathways
involved, will require further study.
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